Delivery Order SPE2DR25D1103-SPE2DR26FE635
- Not listed
- The Defense Logistics Agency awarded a $1,534.20 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on September 22, 2025, with a completion date of September 23, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a $1,323.98 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Lantus SoloStar 100 Unit/ml 3ml insulin pens. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by December 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,095.17 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on December 18, 2025, with completion scheduled for December 19, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $1,222.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. The award was made on December 1, 2025, with an ultimate completion date of December 2, 2025, and represents a non-competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,201.44 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens (3mL) on October 29, 2025, with an ultimate completion date of October 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and primary distribution hub for federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,379.08 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens (3mL format) on August 5, 2025, with completion scheduled for August 6, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a small-value pharmaceutical procurement supporting military and federal healthcare operations. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin injection pens on November 3, 2025, with a contract ceiling value of $3,565.14. This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 4, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,247.31 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract, awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, was competitively awarded with no set-aside designation. This delivery order operates under a firm fixed price arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $1,163.64 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens (3mL units) with an ultimate completion date of November 19, 2025. This non-set-aside, firm fixed-price contract represents a competitively awarded delivery order issued under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be performed and delivered from the contractor's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,443.36 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens, with an ultimate completion date of November 5, 2025. This competitive, firm fixed-price delivery order was issued on November 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the contractor's ability to compete in open...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FE635Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,121.59 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on January 5, 2026, with completion scheduled for January 6, 2026. This competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger federal pharmaceutical supply framework, demonstrating the company's role as a critical vendor for federal medical procurement. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Lantus insulin procurement reflects the type of critical diabetes management medication within the company's extensive portfolio of specialty medications, brand-name and generic drugs, and medical supplies delivered across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 1/4/26 |